BioCentury
ARTICLE | Clinical News

Aviptadil: Completed Phase II enrollment

October 16, 2006 7:00 AM UTC

mondoBIOTECH completed enrollment and treatment of 10 patients in the open-label, German Phase II AVISARCO trial. Patients received 200 µg of inhaled Aviptadil daily for 4 weeks. ...